Amlexanox
UnregulatedAlso known as: Aphthasol, OraDisc A, NNMT/NNMT Inhibitor
MetabolicLast reviewed: April 28, 2026
An anti-inflammatory and anti-allergic compound originally approved for treating aphthous ulcers (canker sores). Gained renewed interest after research showed it inhibits NNMT (nicotinamide N-methyltransferase) and IKKε/TBK1 kinases, pathways involved in obesity and insulin resistance. Being explored as a metabolic optimization compound alongside 5-Amino-1MQ.
Mechanism of Action
Inhibits IKKε (inhibitor of nuclear factor kappa-B kinase subunit epsilon) and TBK1 (TANK-binding kinase 1), which are upregulated in obesity and drive chronic low-grade inflammation and insulin resistance. Also inhibits NNMT, increasing NAD+ availability and energy expenditure. The combined effect improves insulin sensitivity and promotes fat oxidation.
Common Uses
- Metabolic optimization research
- Insulin sensitivity improvement
- Fat loss support (investigational)
- Anti-inflammatory applications
- Aphthous ulcer treatment (original indication)
Known Risks
- Contact dermatitis at application site
- Nausea and diarrhea (oral use)
- Stinging or burning sensation (topical)
- Limited data for metabolic applications in humans
- Discontinued from US market (Aphthasol) — availability limited
Regulatory Status
Previously FDA-approved as Aphthasol (topical paste for canker sores) but voluntarily withdrawn from the US market for commercial reasons (not safety). Not currently approved for metabolic indications. Available through compounding pharmacies and research suppliers.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Oral tablet or topical
Typical Dose
25–50 mg (oral, investigational for metabolic use)
Frequency
Once or twice daily
Cycle Length
8–12 weeks
Metabolic use is off-label and investigational. Original FDA-approved dose was 5% topical paste for oral ulcers. Oral dosing for metabolic effects is based on animal studies — human dose-finding trials are limited. Often discussed alongside 5-Amino-1MQ as NNMT-targeting compounds.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.